| Literature DB >> 33952248 |
Thomas Nicholson1, Aaron Scott1, Matthew Newton Ede2, Simon W Jones3.
Abstract
BACKGROUND: In contrast to cigarettes, electronic cigarette use (E-cigarettes) has grown substantially over the last decade. This is due to their promotion as both a safer alternative to cigarettes and as an aide to stop smoking. Critically, upon E-cigarette use, the user may be exposed to high doses of nicotine in addition to other compounds including flavouring chemicals, metal particulates and carbonyl compounds, particularly in highly vascularised tissues such as bone. However, there has been limited investigation into the impact of E-cigarette usage on bone physiology, particularly over extended time periods and there are no clinical recommendations regarding E-cigarette usage in relation to orthopaedic surgery. This literature review draws together data from studies that have investigated the impact of E-cigarette vapour and its major constituents on bone, detailing the models utilised and the relevant mechanistic and functional results. MAIN BODY: Currently there is a lack of studies both in vivo and in vitro that have utilised E-cigarette vapour, necessary to account for changes in chemical composition of E-cigarette liquids upon vaping. There is however evidence that human bone and bone cells express nicotine receptors and exposure of both osteoblasts and osteoclasts to nicotine, in high concentrations may reduce their viability and impair function. Similarly, it appears that aldehydes and flavouring chemicals may also negatively impact osteoblast viability and their ability to form bone. However, such functional findings are predominantly the result of studies utilising bone cell lines such as MG-63 or Saos-2 cells, with limited use of human osteoblasts or osteoclasts. Additionally, there is limited consideration for a possible impact on mesenchymal stem cells, which can also play an import role in bone repair.Entities:
Keywords: E-cigarette; Nicotine; Osteoblasts; Osteoclasts; Vaping
Year: 2021 PMID: 33952248 PMCID: PMC8097983 DOI: 10.1186/s12950-021-00283-7
Source DB: PubMed Journal: J Inflamm (Lond) ISSN: 1476-9255 Impact factor: 4.981
Fig. 1A potential mechanism to highlight how E-cigarette usage may impact bone
The impact of major E-cigarette vapour constituents on bone cell function
| Constituent | Model | Treatment | Proliferation/viability | Gene Expression | ALP Activity | Bone Nodules | Other Cellular Functions | Ref |
|---|---|---|---|---|---|---|---|---|
| Primary human osteoblasts | 3d, 0.01–50 mM | Up to 0.01 mM increased proliferation, > 1 mM reduced proliferation Reduced proliferation. Cytotoxic at 50 mM | ↑Type I collagen, ostrix, ↓ALP, RUNX2, BSP, osteopontin, osteonectin | – | ↑ with 1 mM | Altered morphology | [ | |
| Primary human osteoblasts | 0.01 μM-10 mM up to 3d | ↑ Proliferation with doses up to 1 μM, ↓ with doses > 0.1 mM | ↑ c-fos with 0.1 μM, 1 h | – | – | – | [ | |
| Primary human osteoblasts | 0.1 μM, 11 and 21d | Cytotoxic | – | – | – | ↑ H2O2 accumulation, activation of caspase 3 and mitochondrial apoptosis pathways | [ | |
| Murine cell line (OCCM.30) | – | ↑ PGE2 | ↓ | Time-dependent increase in nitric oxide production | ||||
| Saos-2 cells | 3 mM, up to 14d | – | OPG, PGE2, no change | ↓ | – | – | [ | |
| MG63 | 0.01 μM- 10 mM 1d- 3d | 0.01–100 μM increased proliferation, 1–10 mM decreased/cytotoxic | Type I Col, ALP, osteocalcin, ↑24 h 0.1 μM-1 mM ↓24 h 1-10 mM, 72 h all dosages | – | – | – | [ | |
| RAW264.7 cells, Treated with RANKL for 7d | 0.01–1 mM, up to 7d | – | ↑ Carbonic anhydrase, α 7 nAch receptor ↓CatK, MMP-9, and V-ATPase d2 | n/a | n/a | ↓multinuclear osteoclasts with large nuclei | [ | |
| MG-63 | Cinnamon flavoured, nicotine-free e-cigarette liquid and condensate, 2d. | ↓ Viability | – | – | – | ↑ in ROS production | [ | |
| U937 and MM6 monocytic cell lines | Diacetyl, cinnamaldehyde, acetoin, maltol, pentanedione, o-vanillin, and coumarin, 0.01–1 mM | ↓ Viability | – | – | – | ↑ IL-8 cytokine secretion ↑ in ROS production | [ | |
| Primary human bronchial epithelial (NHBE) cells | Diacetyl or 2,3-pentanedione, for 1d | – | RNA-seq differentially expressed genes: Diacetyl = 163 genes, 2,3-pentanedione = 568 genes | – | – | Disrupting cilia biogenesis | [ | |
| Human osteogenic sarcoma cell line (U2OS) | 0.001–4 mM formaldehyde, 1-3d | ↓ Proliferation, viability | – | – | – | – | [ | |
| Human bone marrow stem cells cultured in osteogenic conditions | Acetaldehyde (0.1–0.12 mM) and Acrolein (0.01–0.12 mM) 1-28d | ↓ Proliferation, viability | – | ↓ | ↓ with 0.03 mM acrolein, 0.1 mmol/L acetaldehyde | Altered cell morphology Reduced adherence to titanium surface | [ | |
| Mouse primary osteoblastic cells/ MC3T3-E1 murine cell line | 0.04% Acetaldehyde, 1-4d | ↓ Proliferation, viability | ↑ PPARγ ↓ RUNX2, osterix | – | – | Reduced osteoblast differentiation, instead a shift towards adipogenesis | [ | |
| Rat calvarial osteoblasts, bone marrow stromal cells | 0.002% Acetaldehyde, 1-14d | – | ↓ BMP-2, ALDH2 | ↓ | ↓ | – | [ |
RUNX2 Runt-related transcription factor 2, BSP Bone sialoprotein, PGE2 Prostaglandin E2, OPG osteoprotegerin, MMP Matrix metalloproteinase, ROS reactive oxygen species, PPAR-γ Peroxisome proliferator-activated receptor gamma, ALDH2 Aldehyde dehydrogenase 2, Saos-2 / MG-63 - human osteoblast-like cell lines derived from patients with osteosarcoma. RAW264.7 a monocyte/macrophage like cell linage, capable of forming multinucleated osteoclast-like cells), ALP Alkaline phosphatase, CatK Cathepsin K